文献速递血管炎

血管生成与巨噬细胞产物标志物预测巨细胞动脉炎病程及监测血管炎症

Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis.
PubMed 文献 · Rheumatology (Oxford) · 2019-02-25

结果显示基线高VEGF、高血管生成素-1和低YKL-40预测较短的无糖皮质激素缓解时间,血管生成素-2升高与治疗中即将复发相关,钙卫蛋白和YKL-40是监测血管壁炎症的候选标志物。

要点

  • 基线高VEGF、高血管生成素-1和低YKL-40预测GCA患者较短的无糖皮质激素缓解时间。
  • 治疗中血管生成素-2升高与即将复发相关,钙卫蛋白和YKL-40或可用于监测血管壁炎症。
  • 糖皮质激素治疗下调除钙卫蛋白和YKL-40外的所有标志物。

核心结论

  • 基线和治疗中的血管生成标志物可预测GCA病程,有助于分层选择糖皮质激素节约治疗。
  • 钙卫蛋白和YKL-40是监测血管壁炎症的候选标志物。

研究设计与样本

  • 用ELISA/Luminex法测定血清IL-6、血清淀粉样A、可溶性CD163、钙卫蛋白、YKL-40、VEGF、血管生成素-1和-2及sTie2浓度。

主要发现

  • 基线时GCA患者除血管生成素-1外所有标志物血清浓度均高于健康对照。
  • 基线高VEGF(P=0.0025)、高血管生成素-1(P=0.0174)和低YKL-40(P=0.0369)预测较短的无糖皮质激素缓解时间。
  • 治疗中血管生成素-2升高与即将复发相关(P<0.05)。
  • IL-6与急性期标志物及可溶性CD163强相关,但与血管生成标志物、YKL-40或钙卫蛋白不相关。
  • 糖皮质激素治疗下调除钙卫蛋白和YKL-40外的所有标志物,颞动脉组织标志物表达得到确认。

关键数值与推荐

  • 基线高VEGF(P=0.0025)、高血管生成素-1(P=0.0174)和低YKL-40(P=0.0369)预测较短的无糖皮质激素缓解时间。
  • 治疗中血管生成素-2升高与即将复发相关(P<0.05)。

临床怎么用

  • 基线血管生成标志物(VEGF、血管生成素-1、YKL-40)可能用于GCA患者分层,指导糖皮质激素节约治疗。
  • 治疗中监测血管生成素-2可能有助于预警复发,钙卫蛋白和YKL-40或可用于监测血管壁炎症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: GCA, a systemic vasculitis, is characterized by an IL-6-dependent acute-phase response. This response is typically suppressed by treatment rendering CRP/ESR unreliable for monitoring vascular inflammation. Also, there are no accurate biomarkers predicting a non-favourable disease course. Here we investigated macrophage products and markers of angiogenesis as biomarkers for prognosis and monitoring of vascular inflammation. METHODS: Forty-one newly diagnosed, glucocorticoid-naive GCA patients were prospectively followed for relapses and glucocorticoid requirement for a median of 30 months (range 0-71). Serum markers at baseline and during follow-up were compared with 33 age-matched healthy controls and 13 infection controls. Concentrations of IL-6, serum amyloid A, soluble CD163, calprotectin, YKL-40, VEGF, angiopoietin-1 and -2 and sTie2 were determined by ELISA/Luminex assay. RESULTS: Serum concentrations of all markers, but not angiopoietin-1, were elevated in GCA patients at baseline when compared with healthy controls. High VEGF (P = 0.0025) and angiopoietin-1 (P = 0.0174) and low YKL-40 (P = 0.0369) levels at baseline were predictive of a short time to glucocorticoid-free remission. Elevated angiopoietin-2 levels were associated with an imminent relapse during treatment (P < 0.05). IL-6 correlated strongly with acute-phase markers and soluble CD163 but not with markers of angiogenesis, YKL-40 or calprotectin. Glucocorticoid treatment down-modulated all markers except for calprotectin and YKL-40. Tissue expression of markers in temporal arteries was confirmed. CONCLUSION: Markers of angiogenesis at baseline and during treatment predict GCA disease course, suggesting utility in patient stratification for glucocorticoid-sparing therapy. Calprotectin and YKL-40 are candidate markers for monitoring vessel wall inflammation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. van Sleen Y, Sandovici M, Abdulahad WH, et al. Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology (Oxford). 2019. PMID: 30805622. doi:10.1093/rheumatology/kez034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。